Bitcoin price today: dips to $92k as Fed cut doubts spark risk-off mood
Biogen Inc. (NASDAQ:BIIB) stands at a pivotal moment in its corporate journey, balancing growth opportunities in its Alzheimer’s franchise against challenges in its legacy multiple sclerosis business. The biopharmaceutical company, known for its focus on neurological and neurodegenerative diseases, has shown resilience in recent quarters while positioning itself for potential long-term growth through strategic pipeline investments and international expansion.
Financial Performance Shows Stability Amid Transition
Biogen demonstrated solid performance in the first quarter of 2025, delivering top-line and bottom-line beats of 9% and 3%, respectively. The company reported total revenue of $2.43 billion, exceeding both consensus and analyst expectations. Its non-GAAP diluted earnings per share reached $3.02, surpassing consensus estimates by 3%.
Several key products outperformed market expectations, including Skyclarys (+16%), Spinraza (+16%), and Leqembi (+12%). The multiple sclerosis franchise also exceeded projections by 2%, showing resilience despite long-term competitive pressures.
For fiscal year 2025, Biogen maintains its revenue guidance, projecting a mid-single digit year-over-year decline. The company has adjusted its non-GAAP diluted EPS guidance to a range of $14.50 to $15.50, reflecting increased investments in research and development.
Alzheimer’s Franchise Gaining Momentum
The Alzheimer’s disease treatment segment represents a significant growth opportunity for Biogen. Leqembi, developed in partnership with Eisai, has shown remarkable traction with a 395% year-over-year increase in usage and an 11% sequential growth from the previous quarter.
This growth trajectory appears poised to continue following recent regulatory approvals in the European Union and Canada. Analysts note increasing acceptance among neurologists who were initially skeptical about anti-amyloid therapies, suggesting broader adoption potential.
The anticipated approval of maintenance dosing and subcutaneous administration for Leqembi could further accelerate uptake by addressing current treatment bottlenecks. Subcutaneous formulation would significantly improve the patient experience by reducing the frequency of clinic visits and simplifying the administration process.
Analysts point to the success of Eli Lilly’s TB3 trial as a positive catalyst for the entire anti-amyloid antibody class, potentially enhancing market perceptions of Leqembi. This shifting narrative in Alzheimer’s treatment approaches could expand the addressable market substantially.
Competitive Landscape and Market Challenges
Biogen faces competition from Eli Lilly’s recently launched Kisunla (donanemab) in the Alzheimer’s space. While this creates market pressure, analysts suggest there is room for multiple players given the size of the potential patient population. The differentiation in safety profiles between these treatments may also allow for market segmentation based on patient characteristics.
Insurance coverage and reimbursement remain significant hurdles for broader Alzheimer’s treatment adoption. The establishment of specialized clinics, such as Stanford’s Alzheimer’s Care and Treatment clinic, provides a potential model for addressing these challenges, though widespread implementation will take time.
For the Alzheimer’s market to reach its full potential, analysts emphasize the need for improvements in three key areas: access to treatment centers, streamlined diagnosis processes, and approval/reimbursement for blood-based biomarkers. Progress in these areas could substantially expand the market opportunity for Biogen’s Alzheimer’s franchise.
Pipeline Developments and R&D Investment
Biogen has increased its research and development investments, signaling confidence in its pipeline despite the near-term impact on earnings. The company’s presence at the 28th American Society of Gene & Cell Therapy Annual Meeting highlighted its commitment to advancing genetic medicine platforms.
Promising developments in the anti-tau ASO program, in collaboration with Ionis Pharmaceuticals, represent another potential avenue for addressing Alzheimer’s disease through a complementary mechanism to anti-amyloid approaches.
Additional pipeline assets with significant potential include MAPTRx, litifilimab, dapirolizumab pegol, and felzartamab. The latter shows promise in antibody-mediated rejection (AMR), diversifying Biogen’s portfolio beyond neurological conditions.
Multiple Sclerosis and Rare Disease Portfolio
While Biogen’s multiple sclerosis franchise faces long-term competitive pressures, it continues to deliver solid performance in the near term. The company has successfully managed this mature business segment while developing new growth drivers.
Skyclarys, acquired through the Reata deal, has shown strong patient growth, validating Biogen’s acquisition strategy. International revenues for Skyclarys are expected to remain volatile as the company navigates pricing negotiations and market access across different regions, though the long-term growth trajectory appears positive.
Spinraza continues to outperform expectations, demonstrating the durability of Biogen’s established products even as the company transitions toward newer growth drivers.
Valuation Considerations
Analysts present divergent views on Biogen’s valuation. Some highlight that the company trades at approximately 8x earnings, significantly below the sector average and their discounted cash flow valuations, even with conservative estimates for Leqembi and pipeline assets.
This discount is attributed to investor concerns about the gradual Leqembi launch trajectory and perceived limitations in near-term pipeline catalysts. Analysts suggest that as these concerns abate and macroeconomic pressures potentially ease, investors may return to Biogen’s story, particularly in anticipation of a more eventful 2026.
The company’s effective cost management and portfolio restructuring have created a leaner organization with reduced risk profile, which may not be fully reflected in the current valuation.
Bear Case
Can Biogen effectively compete with Lilly’s Kisunla in the Alzheimer’s market?
Biogen faces significant competitive pressure from Eli Lilly’s Kisunla (donanemab) in the Alzheimer’s disease treatment space. Kisunla’s recent launch has created a more crowded market for anti-amyloid therapies, potentially limiting Leqembi’s growth potential. The competition could lead to pricing pressures and challenges in gaining market share, particularly if physicians perceive advantages in Lilly’s offering.
Insurance companies and healthcare systems may also implement preferential coverage policies that favor one treatment over another, further complicating Biogen’s market position. The differentiation in safety profiles between these treatments, particularly regarding amyloid-related imaging abnormalities (ARIA), may influence prescribing patterns in ways that could disadvantage Biogen’s product in certain patient segments.
Will increased R&D spending yield sufficient returns to offset declining MS franchise revenues?
Biogen has reduced its earnings guidance due to increased investments in research and development, creating near-term financial pressure without guaranteed long-term returns. The company’s legacy multiple sclerosis business faces ongoing erosion from competitive pressures, creating a revenue gap that new products must fill to maintain growth.
Historical data in the pharmaceutical industry suggests that increased R&D spending does not always correlate with successful product launches. Many pipeline candidates fail in late-stage clinical trials or achieve only modest commercial success after approval. Biogen’s decision to cut certain programs while increasing overall R&D investment raises questions about the focus and potential return on these investments.
The timeline for realizing returns from current R&D investments extends several years into the future, during which the MS franchise may experience accelerated decline. This timing mismatch creates a potential valley in Biogen’s revenue trajectory that could impact valuation and investor sentiment in the medium term.
Bull Case
How might the approval of Leqembi’s subcutaneous formulation transform its market potential?
The anticipated approval of Leqembi’s subcutaneous (subQ) formulation represents a potential game-changer for Biogen’s Alzheimer’s franchise. This administration route would significantly reduce the burden on healthcare systems by decreasing the frequency of clinic visits and simplifying the treatment process. For patients, subQ administration means less time spent in medical facilities and a more convenient treatment experience.
The current intravenous administration requires specialized infusion centers and trained staff, creating bottlenecks that limit patient access. Subcutaneous delivery would expand the number of facilities capable of administering treatment, potentially accelerating patient onboarding rates. This expansion of treatment capacity could drive substantial revenue growth as more patients gain access to therapy.
Maintenance dosing approval would complement the subQ formulation by reducing the long-term treatment burden, improving patient adherence, and potentially expanding the duration of therapy. These combined innovations could dramatically increase the addressable market for Leqembi, driving revenue growth well beyond current projections.
Could international expansion drive meaningful growth for Biogen’s key products?
Recent regulatory approvals for Leqembi in the European Union and Canada open significant new markets for Biogen’s Alzheimer’s franchise. These regions represent substantial patient populations with aging demographics and increasing Alzheimer’s disease prevalence. The EU approval particularly offers access to multiple healthcare systems with established reimbursement frameworks for innovative therapies.
Skyclarys is also showing promise in international markets, with Biogen actively expanding its global footprint. While international pricing negotiations create short-term revenue volatility, the long-term potential remains substantial as access expands across different regions. The positive patient growth trends observed in existing markets suggest strong demand that could translate to international settings.
Biogen’s established global commercial infrastructure provides advantages in navigating regulatory pathways and reimbursement negotiations across different healthcare systems. This expertise could accelerate the revenue ramp in international markets compared to competitors with less global experience, creating a competitive advantage in the race to serve patients worldwide.
SWOT Analysis
Strengths
- Strong Q1 2025 performance with revenue and EPS beats
- 395% year-over-year increase in Leqembi usage
- Successful cost management and portfolio restructuring
- Solid performance from Skyclarys (+16%) and Spinraza (+16%)
- Established global commercial infrastructure
- Diversified pipeline with multiple potential growth drivers
Weaknesses
- Competitive pressures in legacy MS business
- Slower than expected Leqembi launch trajectory
- Reduced earnings guidance due to increased R&D spending
- Insurance and reimbursement challenges for Alzheimer’s treatments
- Underdeveloped pipeline following recent program cost cuts
- Dependence on Leqembi success for near-term growth narrative
Opportunities
- EU and Canada approvals for Leqembi
- Potential approval of subcutaneous formulation and maintenance dosing
- Promising anti-tau ASO developments with Ionis
- Advancements in genetic medicine platforms
- International expansion for Skyclarys
- Pipeline assets in lupus and antibody-mediated rejection
Threats
- Competition from Eli Lilly’s Kisunla in Alzheimer’s market
- Long-term erosion of MS treatments’ market share
- Regulatory risks for pipeline assets
- Pricing pressures in international markets
- Potential for clinical trial failures in key pipeline programs
- Macroeconomic pressures affecting biotech sector valuations
Analysts Targets
- Stifel - Buy with $202 price target (November 6, 2025)
- RBC Capital Markets - Outperform with $205 price target (May 2, 2025)
- BMO Capital Markets - Market Perform with $128 price target (May 2, 2025)
- Piper Sandler - Neutral with $115 price target (April 29, 2025)
This analysis is based on information available from April 29, 2025, through November 6, 2025.
InvestingPro: Smarter Decisions, Better Returns
Gain an edge in your investment decisions with InvestingPro’s in-depth analysis and exclusive insights on BIIB. Our Pro platform offers fair value estimates, performance predictions, and risk assessments, along with additional tips and expert analysis. Explore BIIB’s full potential at InvestingPro.
Should you invest in BIIB right now? Consider this first:
Investing.com’s ProPicks, an AI-driven service trusted by over 130,000 paying members globally, provides easy-to-follow model portfolios designed for wealth accumulation. Curious if BIIB is one of these AI-selected gems? Check out our ProPicks platform to find out and take your investment strategy to the next level.
To evaluate BIIB further, use InvestingPro’s Fair Value tool for a comprehensive valuation based on various factors. You can also see if BIIB appears on our undervalued or overvalued stock lists.
These tools provide a clearer picture of investment opportunities, enabling more informed decisions about where to allocate your funds.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.